Maravai LifeSciences (NASDAQ:MRVI) Director Gregory Lucier Buys 51,472 Shares

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Director Gregory Lucier purchased 51,472 shares of the business’s stock in a transaction on Friday, December 5th. The stock was acquired at an average cost of $3.70 per share, with a total value of $190,446.40. Following the completion of the acquisition, the director directly owned 106,595 shares in the company, valued at $394,401.50. The trade was a 93.38% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Maravai LifeSciences Price Performance

Shares of MRVI traded up $0.08 during mid-day trading on Tuesday, hitting $3.69. The company’s stock had a trading volume of 1,212,217 shares, compared to its average volume of 2,085,878. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The firm has a 50-day moving average price of $3.33 and a 200 day moving average price of $2.76. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.66 and a fifty-two week high of $6.21. The stock has a market capitalization of $943.57 million, a price-to-earnings ratio of -4.39 and a beta of 0.32.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The company had revenue of $41.63 million for the quarter, compared to analysts’ expectations of $49.02 million. On average, research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MRVI. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada lowered their target price on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.36.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Nuveen LLC acquired a new position in Maravai LifeSciences during the 1st quarter valued at $666,000. Philosophy Capital Management LLC bought a new position in Maravai LifeSciences during the first quarter worth about $5,731,000. Jacobs Levy Equity Management Inc. boosted its stake in Maravai LifeSciences by 437.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company’s stock valued at $1,091,000 after buying an additional 401,673 shares in the last quarter. Strs Ohio acquired a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $429,000. Finally, Parkman Healthcare Partners LLC grew its stake in Maravai LifeSciences by 88.6% during the first quarter. Parkman Healthcare Partners LLC now owns 660,000 shares of the company’s stock worth $1,459,000 after buying an additional 310,000 shares during the last quarter. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.